Amneal Pharmaceuticals
AMRX
154 hedge funds and large institutions have $203M invested in Amneal Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 41 increasing their positions, 52 reducing their positions, and 26 closing their positions.
4% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 26
1% more funds holding
Funds holding: 153 → 154 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.13% less ownership
Funds ownership: 65.9% → 65.77% (-0.13%)
21% less repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 52
36% less capital invested
Capital invested by funds: $316M → $203M (-$113M)
64% less call options, than puts
Call options by funds: $393K | Put options by funds: $1.08M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$4.44M |
| 2 |
Millennium Management
New York
|
+$3M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.91M |
| 4 |
Allspring Global Investments
Charlotte,
North Carolina
|
+$1.35M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
+$1.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EP
Eversept Partners
New York
|
-$2.25M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$1.77M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
-$1.63M |
| 5 |
State Street
Boston,
Massachusetts
|
-$1.33M |
AMRX Hedge Fund Activity: Q3 2022 in Review
154 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Amneal Pharmaceuticals (AMRX) for Q3 2022, worth a combined $203M — down 36% from $316M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new AMRX positions and 26 closed out — a net gain of 1 holder — while 41 added to existing stakes and 52 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $4.44M. The largest seller was Eversept Partners, cutting an estimated $2.25M.
- 154 institutional investors held Amneal Pharmaceuticals (AMRX) as of Q3 2022, up from 153 in Q2 2022.
- Funds reported $203M of Amneal Pharmaceuticals stock for Q3 2022, down 36% quarter-over-quarter.
- 27 funds opened new Amneal Pharmaceuticals positions in Q3 2022 and 26 closed out, a net change of +1 holder.
- The largest Amneal Pharmaceuticals buyer in Q3 2022 was OrbiMed, an estimated $4.44M added.
- The largest Amneal Pharmaceuticals seller in Q3 2022 was Eversept Partners, an estimated $2.25M sold.
Based on aggregated 13F filings for Q3 2022.